募集资金年度存放与使用情况鉴证报告 募集资金年度存放与使用情况鉴证报告 容诚专字[2025]230Z0010 号 欧普康视科技股份有限公司 容诚专字[2025]230Z0010 号 中国·北京 容诚会计师事务所(特殊普通合伙) | | | | 序号 | 内 容 | 页码 | | --- | --- | --- | | 1 | 募集资金年度存放与使用情况鉴证报告 | 1-3 | | 2 | 募集资金年度存放与使用情况专项报告 | 4-12 | 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26 (100037) TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn https://www.rsm.global/china/ 欧普康视科技股份有限公司全体股东： 我们审核了后附的欧普康视科技股份有限公司（以下简称"欧普康视"）董事会 编制的 2024 年度《关于募集资金年度存放与使用情况的专项报告》。 一、 对报告使用者和使用目的的限定 本鉴证报告仅供欧普康视年度报告披露 ...

国元证券股份有限公司关于 欧普康视科技股份有限公司 2024 年度定期现场检查报告 根据中国证监会《证券发行上市保荐业务管理办法》和《深圳证券交易所上 市公司自律监管指引第 13 号——保荐业务》等有关法律法规的要求，国元证券 股份有限公司作为欧普康视科技股份有限公司（以下简称"欧普康视"或"公 司"）2021 年度向特定对象发行股票的保荐机构，于 2025 年 3 月 21 日-3 月 25 日对欧普康视 2024 年 1 月 1 日-2024 年 12 月 31 日期间的有关情况进行了现场 检查，报告如下： | 保荐人名称：国元证券股份有限公司 被保荐公司简称：欧普康视 | | --- | | 保荐代表人姓名：高书法 联系电话：0551-62207572 | | 保荐代表人姓名：葛剑锋 联系电话：0551-62207572 | | 现场检查人员姓名：葛剑锋、张艳 | | 现场检查对应期间：2024 年 1 月 1 日-2024 年 12 月 31 日 | | 现场检查时间：2025 年 3 月 21 日-3 月 25 日 | | 一、现场检查事项 现场检查意见 | | （一）公司治理 是 否 不适用 | ...

国元证券股份有限公司 关于欧普康视科技股份有限公司 2024 年度内部控制自我评价报告的核查意见 国元证券股份有限公司（以下简称"国元证券"或"保荐机构"）作为欧普 康视科技股份有限公司（以下简称"欧普康视"或"公司"）2021 年度向特定 对象发行股票的保荐机构，根据《深圳证券交易所创业板股票上市规则》《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳 证券交易所上市公司自律监管指引第 13 号——保荐业务》《企业内部控制基本 规范》等有关法律法规和规范性文件的要求，对欧普康视 2024 年度《内部控制 自我评价报告》进行了核查，并发表如下核查意见： 一、欧普康视内部控制的基本情况 （一）内部控制评价的依据 公司依据《中华人民共和国公司法》《中华人民共和国证券法》《企业内部 控制基本规范》及其配套指引、《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》以及公司内部相关规章制度的要求，组织开展内 部控制评价工作。 （二）内部控制评价的原则 1、全面性原则：内部控制贯穿决策、监督和执行全过程，覆盖公司的各项 业务和事项。 2、重要性原则：内部控制在全面控 ...

2024 年度独立董事述职报告 欧普康视科技股份有限公司 本人作为欧普康视科技股份有限公司（以下简称"公司"）的独立董事，本 人在任职期间严格按照《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号--创 业板上市公司规范运作》《公司章程》《独立董事任职及议事制度》等相关法律 法规的规定和要求，2024 年度任职期间，忠实、勤勉、尽责、独立地履行职责， 积极出席公司召开的相关会议，本人认真审议董事会的各项议案，独立、客观、 公正地对各项议案和相关事项发表意见，充分发挥了独立董事的独立性、专业性 的作用。现就本人 2024 年度履行独立董事职责情况汇报如下： 各位股东及股东代表： 一、独立董事的基本情况 本人许强，男，1979—1983 年武汉大学物理系毕业，获理学学士。1983 年 8 月—2017 年 12 月，在机械工业部合肥通用机械研究所（院）（1999 年 8 月后 属中国机械工业集团）先后任工程师，室主任，工程部主任，所长助理，1999 年 任副所长（2003 后副院长），2015 年兼任国机通用机械科技股份公司（600444） ...

2024 年度独立董事述职报告 欧普康视科技股份有限公司 各位股东及股东代表： 本人作为欧普康视科技股份有限公司（以下简称"公司"）的独立董事，在 任职期间严格按照《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司独立董事管理办法》《深圳证券交易所上市公司自律监管指引第 2 号--创业 板上市公司规范运作》《公司章程》《独立董事任职及议事制度》等相关法律法 规、规章的规定和要求，在 2024 年度工作中，诚实、勤勉、独立地履行职责， 积极出席相关会议，认真审议董事会各项议案，对公司重大事项发表了意见，充 分发挥了独立董事及各专业委员会的作用。一方面，严格审核公司提交董事会的 相关事项，维护公司和公众股东的合法权益，促进公司规范运作；另一方面发挥 自己的专业优势，积极关注和参与研究公司的发展，为公司的审计工作及内部控 制等工作提出了意见和建议。现就本人 2024 年度履行独立董事职责情况汇报如 下： 一、独立董事的基本情况 本人许立新，男，中国科技大学管理学院副教授、硕士学位。1999 年至今在 中国科学技术大学管理学院任教。自 2020 年 5 月 7 日起出任本公司独立董事。 现任中国科学技术大学 ...

唐民松，男，1963 年出生，中国国籍，无境外永久居留权，硕士学位，高级 律师、安徽省先进律师。安徽承义律师事务所创始合伙人、主任，多年受聘担任 安徽华茂纺织股份有限公司、安徽全柴动力股份有限公司、中共安徽省委办公厅、 蚌埠市人民政府等多家党政机关企业单位常年法律顾问，现任安徽国元信托有限 责任公司独立董事，公司独立董事。 本人作为欧普康视科技股份有限公司（以下简称"公司"）的第四届董事会 独立董事在 2024 年度任职期间严格按照《中华人民共和国公司法》《上市公司 独立董事管理办法》等法律法规、监管规则以及《公司章程》《独立董事任职及 议事制度》的有关规定。本人从事律师行业多年，充分发挥自己的专业优势投入 公司经营管理、公司治理等方面，忠实、勤勉、尽责、独立地履行职责，严格审 核公司提交董事会的相关事项，促进公司规范运作，同时发挥了独立董事及各专 门委员会委员的独立性、专业性的作用，切实维护公司和股东尤其是中小股东的 合法权益。本人现就 2024 年度独立董事履职情况述职如下： 一、独立董事的基本情况 欧普康视科技股份有限公司 2024 年度独立董事述职报告 各位股东及股东代表： 报告期内，本人任职符合《上 ...

一、主要会计数据和财务指标 三、分红送配方案情况 10派2.24元(含税) 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 28844.45万股，累计占流通股比： 43.15%，较上期变化： -664.16万股。 | 名称 持有数量(万股) | | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 南京欧陶信息科技有限公司 | 12279.05 | 18.37 | 不变 | | 陶悦群 | 7472.27 | 11.18 | 不变 | | 合肥欧普民生投资管理合伙企业(有限合伙) | 2905.62 | 4.35 | -460.93 | | 中国银行股份有限公司-华宝中证医疗交易型开放式指数 证券投资基金 | 1746.11 | 2.61 | 新进 | | 中国工商银行股份有限公司-易方达创业板交易型开放式 指数证券投资基金 | 1346.92 | 2.01 | 新进 | | 卢文庆 | 992.51 | 1.48 | 80.36 | | 中国农业银行股份有限公司-中证500交易型开放式指数证 | | | | | 券投资 ...

Financial Performance - The company's operating revenue for 2024 was approximately ¥1.81 billion, representing a 4.40% increase compared to ¥1.74 billion in 2023[25]. - The net profit attributable to shareholders for 2024 was approximately ¥572.23 million, a decrease of 14.16% from ¥666.60 million in 2023[25]. - The net profit after deducting non-recurring gains and losses for 2024 was approximately ¥491.53 million, down 14.12% from ¥572.32 million in 2023[25]. - The total assets at the end of 2024 reached approximately ¥6.03 billion, reflecting a 9.28% increase from ¥5.52 billion at the end of 2023[25]. - The net assets attributable to shareholders at the end of 2024 were approximately ¥4.70 billion, up 7.94% from ¥4.35 billion at the end of 2023[25]. - The basic earnings per share for 2024 was ¥0.6408, a decrease of 14.12% from ¥0.7462 in 2023[25]. - The cash flow from operating activities for 2024 was approximately ¥684.91 million, down 5.32% from ¥723.38 million in 2023[25]. - The weighted average return on equity for 2024 was 12.69%, down from 15.58% in 2023[25]. - The company reported a significant decrease in net profit in the fourth quarter of 2024, with only ¥49.65 million attributable to shareholders[27]. - The company received government subsidies amounting to approximately ¥5.92 million in 2024, compared to ¥4.58 million in 2023[30]. - The company reported a total income of 80,700,962.43, with a significant decrease in non-operating income of -10,863,227.68 compared to previous periods[31]. Market Dynamics - The company reported a significant reliance on high-end medical devices, particularly orthokeratology lenses, which are subject to increasing competition and a potential decline in consumer spending[8]. - The company is one of the selected enterprises for the centralized procurement of orthokeratology lenses in Hebei province, which may impact sales and revenue in the participating regions[6]. - The company’s revenue is heavily concentrated in the East China region, which poses a risk if the business environment in that area deteriorates[9]. - The gross margin for orthokeratology lenses is relatively high, but increased market competition may lead to a decline in this margin, affecting overall performance[10]. - The company is experiencing a slowdown in high-end consumer demand, which could adversely affect its sales performance if the trend continues[7]. - The market for orthokeratology lenses, a key product for myopia control, is facing growth challenges due to increased competition from non-medical frame glasses, although it is expected to recover post-bottleneck[35]. - The company anticipates a recovery in orthokeratology lens sales due to their superior myopia control effectiveness compared to alternative products[52]. - The sales revenue from hard contact lenses, primarily from orthokeratology lenses, declined by 6.73% due to increased competition and a shift towards lower-cost alternatives[47]. - The company’s medical service revenue grew by 20.26%, driven by increased income from its affiliated hospitals[47]. - The company’s direct sales revenue increased by 4.18%, while terminal revenue grew by 13.21%, accounting for 52.91% of total revenue[49]. Product Development and Innovation - The company is preparing to launch a new product, the scleral lens, in 2025, which is expected to have a high market potential due to its superior comfort and vision correction capabilities[41]. - The introduction of low-concentration atropine products for myopia control is anticipated to enhance sales, with one product expected to be approved for sale in 2024[39]. - The company has developed a comprehensive product matrix for myopia control, including orthokeratology lenses, scleral lenses, multifocal soft lenses, and other related products[63]. - The company has initiated new medical device R&D projects, including cataract phototherapy devices and non-contact scoliosis detection devices, achieving significant progress[56]. - The company has successfully completed clinical trials for low-concentration atropine eye drops, which are now in the stability assessment phase[56]. - The company has developed and launched several new products, including an eye massage device and an automatic inversion camera, contributing to its product portfolio expansion[79]. - The company is in the late clinical trial phase for a new soft contact lens designed to reduce myopia progression[102]. - The company is focusing on expanding its product line with new technologies, including a cataract therapy device and a high-oxygen-permeable contact lens[103]. - The company is developing a range of new products, including AI eye protection glasses and automated lens cleaning devices, to expand its product offerings[155]. Operational Challenges and Risks - The company faces legal risks associated with the long-term use of its optical devices, which could lead to lawsuits and impact its reputation and financial standing[6]. - The company has been expanding its business network through the establishment of subsidiaries, which increases management complexity and potential internal control risks[10]. - The company has established a risk prevention system that includes product quality control and customer usage tracking, improving its risk resistance capabilities[70]. - The company is addressing the risk of high-end consumer fatigue by offering product discount packages and expanding its product matrix[169]. - The company is actively reducing risks associated with centralized procurement policies by developing new products and enhancing service quality[167]. - The company has a cautious approach to investment and mergers, ensuring that most targets are established optical service enterprises with sustainable profitability, and includes operational requirements and compensation clauses in investment agreements[172]. Strategic Initiatives - The company plans to continue expanding its business with high quality despite the slow investment progress in certain projects[132]. - The company aims to expand into broader optical product fields and services, driven by a dual strategy of "full optical products" and "year-round optical services" to inject new vitality into future development[181]. - The company is committed to enhancing its leadership in the rigid contact lens industry by increasing investment in R&D, production capacity, and quality improvement[149]. - The company is focusing on the development of new rigid lens materials, with the second-generation material (OVCTEK 200) in the technical review stage and the third-generation material (OVCTEK FX) having passed registration inspection[155]. - The company has established a strategy to explore investment opportunities in other health service markets, such as dental and rehabilitation services, leveraging its operational model in optical services[152]. Governance and Investor Relations - The company has established a performance evaluation incentive system linking management compensation to business performance and objectives[188]. - The company maintains a complete and independent business structure, ensuring no reliance on related parties for production and operations[191]. - The company has a governance structure that complies with relevant laws and regulations, with no unresolved governance issues[186]. - The cash dividend distribution plan reflects the company's commitment to sharing development results with investors, with a continuous increase in the dividend ratio from 2022 to 2024[182]. - The company will hold an annual performance briefing after the 2024 annual report disclosure to enhance investor communication and confidence[183]. - The company has a diverse board of directors with expertise in various fields, including engineering, medicine, and law, enhancing its strategic decision-making capabilities[198].

关于持股5%以上股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 欧普康视科技股份有限公司（以下简称"公司"）于近日收到公司持股 5% 以上股东南京欧陶信息科技有限公司（以下简称"南京欧陶"）通知，获悉其将 前期质押给广发证券股份有限公司的 187.03 万股解除质押。现将具体情况公告 如下： 一、股东股份解除质押的基本情况 | 股东 名称 | 是否为 控股股 东或第 一大股 东及其 | 本次解除质 押股份数量 （股） | 占其所 持股份 比例（%） | 占公司 总股本 比例（%） | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 一致行 动人 | | | | | | | | 南京 欧陶 | 否 | 871,500 | 0.77 | 0.10 | 2023/11/8 | 2025/3/17 | 广发证券股份有限公司 | | | | 51,000 | 0.05 | 0.01 | 2024/1/31 | 2025/3/17 | | | | ...

| 股东 名称 | 是否为 控股股 东或第 一大股 东及其 一致行 动人 | 本次解除质 押股份数量 （股） | 占其所 持股份 比例（%） | 占公司 总股本 比例（%） | 起始日 | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | 南京 | 否 | 2,420,851 | 2.14 | 0.27 | 2023/7/6 | 2025/3/12 | 广发证券股份有限公司 | | | | 185,000 | 0.16 | 0.02 | 2024/9/13 | 2025/3/12 | 广发证券股份有限公司 | | | | 810,000 | 0.72 | 0.09 | 2024/1/22 | 2025/3/12 | 广发证券股份有限公司 | | | | 300,000 | 0.27 | 0.03 | 2024/7/4 | 2025/3/12 | 广发证券股份有限公司 | | 欧陶 | | 201,000 | 0.18 | 0.02 | 2024/8/21 | 2025/3/12 | 广发证券股份有限公司 | | | | 700,0 ...